Skip to main content
. 2021 Jan 21;29(5):1729–1743. doi: 10.1016/j.ymthe.2021.01.020

Figure 4.

Figure 4

PTGFRN enables EV surface display of protein cargo

(A) EV membrane highlighting the classes of proteins displayed by fusion to PTGFRN. (B) In vitro activity of EVs displaying IL-7. Mean values from 4 donors using 2 EV isolations were compared by 1-way ANOVA and a Tukey post hoc test. ∗p = 0.0108; Rec., recombinant IL-7. (C) In vitro activity of EVs displaying CD40L. Mean values from 4 donors using 2 EV isolations were compared by 1-way ANOVA and a Tukey post hoc test. ∗p = 0.0247; ∗∗∗∗p < 0.0001; Rec., recombinant CD40L ECD. (D) In vitro activity of EVs displaying αCD3 scFab. Mean values are shown from individual mouse spleens using 2 EV isolations. Rec., recombinant αCD3. (E) In vitro activity of EVs displaying IL-12. Mean values from 4 donors using 2 EV isolations were compared by 1-way ANOVA and a Tukey post hoc test (ng/mL) or an unpaired t test (p/mL). Rec., recombinant IL-12; ns, not significant. (F) In vivo activity of EVs displaying murine IL-12 (FL) compared to treatment with recombinant murine IL-12 (Rec.) at 100 and 200 ng doses. Percentages of reduction in tumor volume compared to PBS treatment are given. Independent EV isolations were used for each study and data were compared by 1-way ANOVA and a Tukey post hoc test. ∗p < 0.05; ∗∗∗p < 0.0005; ∗∗∗∗p < 0.0001; ns, not significant. (G) Survival of EV-treated animals compared to recombinant murine IL-12. 100 ng, p = 0.0209; 200 ng, p = 0.0421 by Gehan-Breslow-Wilcoxon test.